Archives

by in
Entry Author Date Location
Former Dendreon CEO Gold Working on New Cancer Drug Startups 10/13/14 Wisconsin
Former Dendreon CEO and Dendreon Bull Start New Biotech Hedge Fund 09/03/13 Seattle
Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study 05/15/13 San Francisco
Genomic Health Test Aims To Cut Overtreatment of Prostate Cancer 05/08/13 San Francisco
Lessons For Drug Development From The Aveo Buzzsaw 05/06/13 National
Tokai Looks to Follow Fast Behind J&J, Medivation in Prostate Cancer 02/13/13 Boston
Crowdfunding Is Coming to Biotech, so Get Ready for a Wild Ride 01/28/13 National
Exelixis and Onyx Await Their Cancer-Drug Fates 09/18/12 San Francisco
The FDA Turns Friendly Toward Pharma in 2012 09/10/12 National
OncoGenex Waits, and Waits, For Data on Prostate Cancer Drug 08/02/12 Seattle
ASCO Wrap-Up: A Summary of This Week’s Cancer R&D Headlines 06/05/12 National
Medivation Emerges With New Prostate Cancer Drug 05/31/12 San Francisco
ASCO Preview: Eight Cancer Drugs to Watch at the Big Show 05/14/12 National
Seattle Genetics Misses 1st Quarter Sales Estimate, But Sees $1B Future 05/08/12 Seattle
Seattle Genetics Digs Deeper Into the Proverbial Haystack 03/13/12 National
Dendreon Stock Tumbles As Company Projects ‘Moderate’ Sales Growth 02/27/12 Seattle
Analyst: Seattle Genetics on Pace to Smash Wall Street Forecast with Lymphoma Drug Rollout 10/20/11 Seattle
Dendreon Takes Huge Hit, Stock Tanks 60% on Sales Shortfall 08/03/11 Seattle
Seattle Genetics’ FDA Panel Preview: What You Need to Know This Week 07/12/11 Seattle
Dendreon, After Yearlong Inquiry, Sways Medicare to Pay for $93,000 Prostate Cancer Drug 06/30/11 Seattle
ASCO Wrap-Up: The Skinny on Cancer News From All Corners of the U.S. 06/07/11 National
Exelixis Zeroes in on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients 06/06/11 San Francisco
Dendreon Wins Full Reimbursement From Medicare for $93K Prostate Cancer Drug 03/30/11 Seattle
Think Obamacare Will Suffocate New Drug Development With Price Controls? Think Again 03/21/11 National
Gilead Wagers $600M on Calistoga, Dendreon Scopes New Digs, Physio to Spin Off, & More Seattle-Area Life Sciences News 02/24/11 Seattle
Want to Create More Startups? Do More to Corral Health Insurance Costs 02/17/11 Seattle
Dendreon Prepares to Take Some Heat in the Other Washington Over Cancer Drug Prices 11/16/10 Seattle
ZymoGenetics CEO Doug Williams Exits the Stage, Mulls Next Free Agent Move 11/08/10 Seattle
Dendreon’s Provenge Launch Story Enters Second Chapter, With Today’s Earnings Call 11/03/10 Seattle
Dendreon Misses Wall Street’s (Already Low) Expectations for Provenge Sales 08/03/10 Seattle
Page 1 of 2 next page »